bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIAF bioAffinity Technologies, Inc.

Trading 08-10 15:52:52 EDT

0.4990

-0.0110

-2.16%

High0.5200	Low0.4990	Vol502.55K
Open0.5000	D1 Closing0.5100	Amplitude4.12%
Mkt Cap4.04M	Tradable Cap4.00M	Total Shares8.10M
T/O256.09K	T/O Rate6.27%	Tradable Shares8.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":0.499,"timestamp":1786391536366,"preClose":0.51,"halted":0,"volume":502554,"delay":0,"changeRate":-0.02156862745098041,"floatShares":8020196,"shares":8101700,"eps":-3.980202,"marketStatus":"Trading","change":-0.011,"latestTime":"08-10 15:52:52 EDT","open":0.5,"high":0.52,"low":0.499,"amount":256092.85436904003,"amplitude":0.041176,"askPrice":0.5016,"askSize":600,"bidPrice":0.49,"bidSize":10401,"shortable":3,"etf":0,"ttmEps":-3.980202,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786392000000},"marketStatusCode":2,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":0.51,"preHourTrading":{"tag":"盘前","latestPrice":0.5101,"preClose":0.51,"latestTime":"09:08 EDT","volume":4349,"amount":2219.7306437599996,"timestamp":1786367293201,"change":0.0001,"changeRate":0.000196,"amplitude":0.027647},"postHourTrading":{"tag":"盘后","latestPrice":0.5096,"preClose":0.51,"latestTime":"19:47 EDT","volume":34480,"amount":17663.0704,"timestamp":1786146477142,"change":-0.0004,"changeRate":-0.000784,"amplitude":0.020392},"volumeRatio":1.690556},"requestUrl":"/m/hq/s/BIAF/wiki","defaultTab":"wiki","newsList":[{"id":"2658593507","title":"Heron Therapeutics Q2 Revenue Rises on Acute Care Growth, Withdraws 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593507","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593507?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:08","pubTimestamp":1786363720,"startTime":"0","endTime":"0","summary":"Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlookOverviewUS biotechnology firm's Q2 net revenue rose 1.3% yr/yr to $37.7 mlnCompany withdrew full-year 2026 guidance citi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRTX","BK4007","BIAF","LU2324357040.USD","PTH","BK4139","AXSM","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645690","title":"bioAffinity Technologies Q2 Net Income USD -3.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645690?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:30","pubTimestamp":1786105848,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nPLX0BPSG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643239","title":"bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643239","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643239?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:11","pubTimestamp":1786104668,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(2.40) by 73.33 percent. This is a 87.45 percent increase over losses of $(5.10) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61035878/bioaffinity-technologies-q2-eps-0-64-beats-2-40-estimate-sales-1-511m-beat-1-483m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657439356","title":"bioAffinity Q2 FY26 Net Loss Narrows to $3.4 Million; Revenue Rises 19% to $1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657439356","media":"Reuters","labels":["shareholding","corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657439356?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:02","pubTimestamp":1786104146,"startTime":"0","endTime":"0","summary":"bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 millionbioAffinity Technologies posted Q2 revenue of USD 1.5 million, up 19% year over year; net loss narrowed to USD 3.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLbFjsR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657435706","title":"Press Release: bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2657435706","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657435706?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:00","pubTimestamp":1786104000,"startTime":"0","endTime":"0","summary":"CyPath Lung test volume increased 216% year over year in Q2 2026Company drives physician adoption of CyPath Lung and advances longitudinal clinical trialPipeline expands to include development of precision diagnostics for asthma and COPD and dermally delivered skin cancer therapeuticsSAN ANTONIO, Texas----August 07, 2026--bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases and topically delivered therapeutics for squamous and basal cell skin cancers, today reported financial results and business highlights for the quarter ended June 30, 2026.Q2 2026 Highlights and Recent Events--  CyPath Lung diagnostic test volume increased 216% during the second. quarter of 2026 compared to the second quarter of 2025.--  CyPath Lung testing revenue for the first six months of 2026 increased. 159% to approximately $835,000, compared with approximately $323,000 for. --  The Comp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4232","R","CLIA","BK4022","NPV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391721","title":"bioAffinity Technologies Faces NASDAQ Delisting Risk After Shares Trade Below $1 Bid-price Minimum","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391721","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391721?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:15","pubTimestamp":1785532544,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies faces Nasdaq delisting risk after shares trade below $1 bid-price minimumbioAffinity Technologies received a Nasdaq staff determination for failing the $1 minimum bid price ru","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL5qHKsg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654101030","title":"BioAffinity announces publication of clinical review on CyPath Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2654101030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654101030?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:15","pubTimestamp":1785154508,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gord...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-announces-publication-of-clinical-review-on-cypath-lung-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-announces-publication-of-clinical-review-on-cypath-lung-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654299017","title":"bioAffinity Publishes Clinical Framework Targeting Pulmonary Nodule Risk Stratification Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2654299017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654299017?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:09","pubTimestamp":1785154144,"startTime":"0","endTime":"0","summary":"bioAffinity publishes clinical framework targeting pulmonary nodule risk stratification marketbioAffinity Technologies published a clinical review outlining a framework for pulmonary nodule risk strat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL6YZpx8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757052","title":"Bioaffinity Technologies - Tests Expected to be Offered as Laboratory Developed Tests Under Clia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757052","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757052?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:08","pubTimestamp":1784722101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0IE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139","BIAFW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653057757","title":"Bioaffinity Technologies - Partners with Pictor to Develop Asthma and Copd Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2653057757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653057757?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:08","pubTimestamp":1784722101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BIAFW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649809449","title":"Bioaffinity Quarterly Cypath Lung Test Sales Double, up More than 200% Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2649809449","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649809449?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:46","pubTimestamp":1783428414,"startTime":"0","endTime":"0","summary":"bioAffinity quarterly CyPath Lung test sales double, up more than 200% year over yearbioAffinity Technologies reported Q2 2026 CyPath Lung test sales up more than 30% from Q1 2026, doubling to a new q","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLb2WcXg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648567521","title":"Bioaffinity to Join Navref-hosted Webinar on Philips-led US Veterans Lung Screening Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648567521","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648567521?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:20","pubTimestamp":1782854414,"startTime":"0","endTime":"0","summary":"bioAffinity to join NAVREF-hosted webinar on Philips-led US veterans lung screening programbioAffinity Technologies will join a NAVREF-hosted webinar on July 21, 2026, focused on lung health screening","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL5xlhTf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["4DX.AU","BIAF","BK7094","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902239","title":"BioAffinity will present preclinical findings on small interfering RNAs","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645902239?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:09","pubTimestamp":1782130189,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs that kill squam...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-will-present-preclinical-findings-on-small-interfering-rnas-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-will-present-preclinical-findings-on-small-interfering-rnas-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645302464","title":"bioAffinity reports positive preclinical data for siRNA therapy targeting squamous, basal skin cancer cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2645302464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645302464?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:01","pubTimestamp":1782129688,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies will present preclinical in vitro findings at the 2026 RNA Therapeutics  Symposium.The study showed its proprietary siRNA approach selectively killed or slowed squamous and basal skin cancer cells while sparing healthy skin cells.The results support development of a topical treatment strategy for two high-incidence skin cancers where surgery can leave residual disease or recurrence risk.No human testing has been conducted, with no FDA IND filed for the program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL2LPJmn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024521","title":"bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024521?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2DKRNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAFW","BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644403855","title":"BioAffinity Technologies Closes $3.2 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644403855","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644403855?lang=en_us&edition=fundamental","pubTime":"2026-06-19 01:25","pubTimestamp":1781803513,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies  said Thursday it closed a public offering of 4 million common shares and pre-funded warrants at $0.80 apiece for gross proceeds of $3.2 million.Each pre-funded warrant is exercisable for one common share and is immediately exercisable, according to a statement.Price: 0.85, Change: +0.01, Percent Change: +1.62","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644038389","title":"bioAffinity Technologies closes USD 3.2 million follow-on offering priced at USD 0.8 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2644038389","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644038389?lang=en_us&edition=fundamental","pubTime":"2026-06-19 01:16","pubTimestamp":1781802978,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies closed a $3.2 million public offering of common stock.Issued 4,000,000 shares, or pre-funded warrants in lieu, priced at $0.80 per share or $0.793 per pre-funded warrant.Pre-funded warrants are immediately exercisable for one share, expiring only when fully exercised.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1tn6pr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644388090","title":"bioAffinity Technologies Announces Closing of $3.2 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644388090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644388090?lang=en_us&edition=fundamental","pubTime":"2026-06-19 01:16","pubTimestamp":1781802960,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUA2V66KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139","BIAFW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644741423","title":"bioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644741423","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644741423?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:54","pubTimestamp":1781704461,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies  shares fell 13% in Wednesday trading after it said it has priced a public offering of 4 million shares of common stock, or pre-funded warrants in lieu thereof, at $0.80 per share for gross proceeds of $3.2 million.The biotech firm said it expects the offering to close Thursday.Investors may instead purchase pre-funded warrants at $0.793 each, with each warrant exercisable for one share of common stock.Price: 0.83, Change: -0.12, Percent Change: -12.22","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644074198","title":"BioAffinity Technologies prices 4M shares at 80c in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644074198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644074198?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:30","pubTimestamp":1781703010,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2M, bef...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-prices-4m-shares-at-80c-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-prices-4m-shares-at-80c-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioaffinitytech.com;ir.bioaffinitytech.com","stockEarnings":[{"period":"1week","weight":-0.1871},{"period":"1month","weight":-0.3536},{"period":"3month","weight":-0.7488},{"period":"6month","weight":-0.4008},{"period":"1year","weight":-0.9393},{"period":"ytd","weight":-0.5678}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.125018},{"month":2,"riseRate":0.25,"avgChangeRate":-0.070787},{"month":3,"riseRate":0.5,"avgChangeRate":0.528916},{"month":4,"riseRate":0.75,"avgChangeRate":0.175283},{"month":5,"riseRate":0,"avgChangeRate":-0.203542},{"month":6,"riseRate":0.25,"avgChangeRate":-0.147014},{"month":7,"riseRate":0.5,"avgChangeRate":-0.002263},{"month":8,"riseRate":0,"avgChangeRate":-0.209508},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.17769},{"month":10,"riseRate":0.25,"avgChangeRate":-0.105345},{"month":11,"riseRate":0.25,"avgChangeRate":-0.068737},{"month":12,"riseRate":0,"avgChangeRate":-0.246482}],"exchange":"NASDAQ","name":"bioAffinity Technologies, Inc.","nameEN":"bioAffinity Technologies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bioAffinity Technologies, Inc.,BIAF,bioAffinity Technologies, Inc.股票,bioAffinity Technologies, Inc.股票老虎,bioAffinity Technologies, Inc.股票老虎国际,bioAffinity Technologies, Inc.行情,bioAffinity Technologies, Inc.股票行情,bioAffinity Technologies, Inc.股价,bioAffinity Technologies, Inc.股市,bioAffinity Technologies, Inc.股票价格,bioAffinity Technologies, Inc.股票交易,bioAffinity Technologies, Inc.股票购买,bioAffinity Technologies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction